MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.24
−0.65%Oct 29, 2026, 20:29 UTC
Mineralys Therapeutics terminated its License Agreement with Tanabe Pharma, and Tanabe assigned the transferred intellectual property to Mineralys under a Termination Agreement.
Oct 28, 2026, 20:05 UTC
Mineralys Therapeutics, Inc. announced that it will report financial results for the third quarter ended September 30, 2026, after market close on November 4, 2026.
Source:Oct 28, 2026, 11:05 UTC
Mineralys Therapeutics, Inc. announced publication of Phase 2 Explore-CKD trial results showing that lorundrostat 25 mg once daily added to an SGLT2 inhibitor met the primary endpoint with a statistically significant reduction in systolic blood pressure at four weeks.
Source:Oct 22, 2026, 22:40 UTC
Mineralys Therapeutics, Inc. presented new Phase 3 Launch-HTN trial data showing similar significant blood pressure reductions with lorundrostat in participants with and without chronic kidney disease, with consistent reductions across CKD stages 1–3.
Source:Oct 9, 2026, 13:00 UTC
Mineralys Therapeutics, Inc. presented new analyses from the pivotal Mineralys Therapeutics, Inc. showing that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target.
Source:Oct 2, 2026, 20:30 UTC
Mineralys Therapeutics announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, held October 21-25 in Denver, Colorado.
Source:Oct 1, 2026, 20:05 UTC
Mineralys Therapeutics announced that five abstracts on its lorundrostat data will be presented at the American Heart Association Hypertension Scientific Sessions 2026 in Arlington, Virginia, on October 7-11.
Source:Sep 23, 2026, 20:05 UTC
Mineralys Therapeutics announced that new long-term efficacy and safety data from its ongoing Transform-HTN open-label extension trial of lorundrostat will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago on November 6-9.
Source:Aug 11, 2026, 23:05 UTC
Mineralys Therapeutics reported a wider second-quarter loss, driven largely by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp.
Aug 11, 2026, 20:05 UTC
Mineralys Therapeutics appointed Dr. Terry Ferguson as Chief Medical Officer to lead medical and late-stage clinical activities.
Source:Jun 3, 2026, 10:05 UTC
Mineralys Therapeutics priced an underwritten offering of 5,660,378 shares of common stock at $26.50 per share, expecting gross proceeds of approximately $150 million.
Source:Jun 3, 2026, 10:00 UTC
Mineralys Therapeutics repurchased royalty obligations in the Tanabe license agreement for $200 million upfront and up to $100 million in milestones, with concurrent financing.
Jun 3, 2026, 00:00 UTC
Mineralys Therapeutics, Inc. entered into a $500 million senior secured term loan facility agreement on June 2, 2026.
May 30, 2026, 15:20 UTC
Mineralys Therapeutics presented new data at a European medical conference showing its experimental drug significantly reduced blood pressure in chronic kidney disease patients.
Source: